Son Sang-Hyun, Kang Jinhong, Ahn Myunghwan, Nam Soyeon, Jung Yong Woo, Lee Ki Yong, Jeon Young Ho, Byun Youngjoo, Lee Kiho
College of Pharmacy, Korea University, 2511 Sejong-ro, Sejong 30019, Korea.
Institute of Pharmaceutical Science and Translational Research, Korea University, 2511 Sejong-ro, Sejong 30019, Korea.
Pharmaceutics. 2021 Sep 19;13(9):1516. doi: 10.3390/pharmaceutics13091516.
Baicalein (5,6,7-trihydroxy-2-phenyl-4H-1-benzopyran-4-one), a flavonoid analog from , possesses several pharmacological activities including antioxidant, antiproliferative, and anti-inflammatory activities. We previously reported that baicalein inhibits the thymic stromal lymphopoietin (TSLP)/TSLP receptor (TSLPR) signaling pathways and can be used as an active ingredient in the treatment of asthma and atopic dermatitis. However, baicalein is rapidly metabolized to baicalin and baicalein-6--glucuronide in vivo, which limits its preclinical and clinical use. In this study, we designed, synthesized, and evaluated baicalein prodrugs that protect the OH group at the 7-position of the A ring in baicalein with the amino acid carbamate functional group. Comprehensive in vitro and in vivo studies identified compound as a baicalein prodrug candidate that improved the plasma exposure of baicalein in mouse animal studies. Our results demonstrated that this prodrug approach could be further adopted to discover oral baicalein prodrugs.
黄芩素(5,6,7-三羟基-2-苯基-4H-1-苯并吡喃-4-酮)是一种源自[具体来源未给出]的黄酮类类似物,具有多种药理活性,包括抗氧化、抗增殖和抗炎活性。我们之前报道过黄芩素可抑制胸腺基质淋巴细胞生成素(TSLP)/TSLP受体(TSLPR)信号通路,并且可用作治疗哮喘和特应性皮炎的活性成分。然而,黄芩素在体内会迅速代谢为黄芩苷和黄芩素-6-O-葡萄糖醛酸,这限制了其在临床前和临床中的应用。在本研究中,我们设计、合成并评估了用氨基酸氨基甲酸酯官能团保护黄芩素A环7位羟基的黄芩素前药。全面的体外和体内研究确定化合物[具体化合物未给出]为黄芩素前药候选物,在小鼠动物研究中提高了黄芩素的血浆暴露量。我们的结果表明,这种前药方法可进一步用于发现口服黄芩素前药。